Elevated IL-6 and CCL5 (RANTES), decreased CD8 cell count and SARS-CoV-2 viral hemorrhage were observed in 10 patients with severe COVID-19. The figure shows that not only IL-1, IL-6, and IL-8, but also RANTES also increased in relation to severity.
Following administration of the CCR5 inhibitor leronlimab, the CCR5 inhibitor can inhibit its action because it works in conjunction with complete inhibition of the CCR5 receptor in macrophages and T cells and - significant confirmation significant confirmation significant confirmation significant confirmation significant confirmation - confirmation confirmation - confirmation - confirmation - confirmation - confirmation
May 19 ANSWER TO. @ influenzer3 The figure shows (a) a decrease in IL-6, (b) an increase in CD8 cells, and (c) the resulting normalization of the CD4/8 ratio over time after treatment.
May 19 Consistent with the decrease in IL-6, single cell RNA sequencing showed a decrease in cluster of myeloid cells expressing IL-6 and its related genes. This is a new approach to reduce viral hemorrhage by disrupting the CCL5-CCR5 axis through positive immunosuppression and immunization.
CYDY's patents are related to CCL5 Inhibition, and is included in the footnotes of the since withdrawn patent regarding malavilock. CYDY's pending patents can be found here: